Benjamin Schwarz

Company: Thymmune Therapeutics

Job title: Associate Director

Seminars:

Strategic Selection of iPSC Starting Lines to Enhance Safety, Consistency & Manufacturability 12:00 pm

Evaluating donor variability and genomic stability Predicting differentiation potential and therapeutic performance of cell linesRead more

day: Day Two Track B Morning

Balancing Quality, Consistency & Scalability of Starting Cell Lines through Strategic Selection 9:10 am

Choosing the right iPSC starting line is fundamental to influencing safety, efficacy, and manufacturability. Key factors such as donor selection, genomic stability, and differentiation potential must be carefully evaluated alongside evolving regulatory expectations. This session will explore best practices for optimizing cell line selection, balancing standardization with therapy-specific requirements.Read more

day: Pre-Conference Workshop Day